Roche Diagnostics  

Elecsys^® TnT Gen 5 (hsTnT) delivers industry-leading sensitivity and precision of <4% CV at all cutoffs¹.  With its 9-minute turnaround time, the assay is a critical diagnostic aid for patients with chest pain – where every minute counts in getting the best treatment to those at greatest risk.

With a wide measuring range of 6–10,000 ng/L, combined with sex-specific cutoffs, the TnT Gen 5 (hsTnT) is the ONLY solution in the U.S. meeting the IFCC guidelines² for high sensitivity¹ and delivering optimal precision per the Third Universal Definition of Myocardial Infarction³.

TnT Gen 5 (hsTnT) enables Emergency Departments clinicians and hospital administrators the opportunity to realize improved management of patients with chest pain and the associated efficiency benefits.

The VENTANA DP 200 slide scanner’s low-volume capacity is well-suited for first-time digital pathology users, remote site scanning, frozen section scanning, and more. Within the VENTANA DP 200 slide scanner are only two moving parts. Automated slide calibration delivers consistent and robust system performance ensuring high system reliability. Along with this are new innovative optics providing superb image quality for various tissue types, including frozen sections. The tray-based system within the VENTANA DP 200 slide scanner eliminates slide handling errors within the instrument. The dynamic focus with high-speed scanning enables fast time to view. Scan times are 20x magnification at less than 45 seconds and 40x at less than 85 seconds.

The Elecsys^® BRAHMS PCT assay is intended for the mortality risk assessment and management of sepsis patients. Featuring a short duration time of only 18 minutes, the Elecsys^® BRAHMS PCT assay can be easily added to any of the automated cobas^® immunoanalyzer platforms, making it ideal for institutions seeking  the advantages of automation. The assay delivers a broad measuring range with excellent low-end sensitivity and precision.  Further, Roche has submitted a 510k to the FDA to expand claims to aid in decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) – defined as (CAP) and (aeCOPD) – and on antibiotic discontinuation for patients with suspected or confirmed sepsis.

Roche is pleased to introduce the new Hydrocodone (HYD), Buprenorphine (BUP), and 6-Acetylmorphine (6-AM) assays, which expand its existing Drugs of Abuse Testing menu offering.  These screening assays are available on the cobas® c 501 & 502 analyzers, allowing for quick response to growing testing demands due to the opioid epidemic.  HYD and BUP are designed to detect specifically one parent drug and the main metabolite in human urine while 6-AM detects the unique metabolite of heroin. All assays can be used in the qualitative and semi-quantitative modes, while providing very stable shelf life and onboard stability. Additionally, HYD and BUP are the only assays in the market to provide two cutoffs while 6-AM provides excellent precision.

cobas^® connection modules (CCM) offer customers the ability to connect to the Roche standalone automation portfolio directly to Roche analytics without compromising the flexibility of the standalone automation concept.

Based on its design, this high-volume automation solution adds value to a laboratory environment by providing convenient sample loading, quality and quantity checks, workflow flexibility and multidisciplinary connectivity, such as hematology and coagulation. Roche is the first IVD vendor to connect molecular testing solutions validated for cross-contamination compliance.

ToRCH is an acronym of the five infections covered by the panel: Toxo, Other disease (including HIV, syphilis, and HBV), Rubella, CMV, and HSV.¹ During pregnancy or delivery, a mother can pass any one of these infections onto her child. Early detection and treatment of particular infections is crucial for preventing complications in newborns.² Provide reliable prenatal screening with an extensive Elecsys ToRCH panel offered by Roche.  This panel combines assays with high clinical sensitivity and specificity.Roche is able to provide a complete ToRCH panel that offers multiple benefits in as little as 18 minutes. Consolidation of ToRCH panel on cobas® immunology analyzers provides greater efficiency for your laboratory. 

With the CLIA-waived cobas Liat PCR System, clinicians are able to make optimal treatment decisions precisely when patients need them most. This is made possible with:

• PCR accuracy
• Quick, definitive results in 20 minutes or less (no need for interpretation)
• Fast, easy operation (walkaway after 1 minute hands-on time)

There are currently three CLIA-waived tests that can be performed in 20 minutes or less:

• cobas Liat Influenza A/B — comprehensive strain coverage

• cobas Liat Influenza A/B and RSV — one test, one sample, three results, zero age restrictions

• cobas Liat Strep A — no confirmation required

Consider what accurate and actionable results would do for you, your institution and your patients.

The cobas^® e 801 module is the most powerful immunoassay analyzer Roche has engineered to date. Built for the growing lab, this standardized platform eliminates testing bottlenecks with nearly double the throughput in the same footprint as its predecessor; perfects reagent management with 48 channels, features on-the-fly loading and 112-day on-board stability, and requires up to six times less blood from the smallest patients. The cobas^® e 801 module was designed to address the most critical pain points, enabling labs to accomplish more every day.

The cobas^® 6800/8800 systems are not mere instruments—they’re strategies for molecular leadership. These moderate complexity systems are creating new realities for how labs of all sizes can add distinctive value, not only throughout their lab, but their entire health system. Offering ready-to-use reagents, refrigerated storage, high throughput, and no daily maintenance requirements, this unprecedented automation can provide transformative efficiency gains. With a broad and expanding assay menu, labs have unlimited possibilities for clinical and operational excellence through real-time PCR technology, which has been proven in clinical trials and in the real world—providing continuity of care for patients, physicians and laboratorians.

Featuring innovative Bloodhound® technology, the cobas m 511 counts and classifies cells using digital multispectral analysis.  Individual cells are imaged directly from the slide. Based on these images, the Bloodhound^® technology counts, and classifies cells to provide a standard CBC, five-part differential, and reticulocyte count.

Using only 30µL of sample, the cobas m 511 unique slide preparation provides a consistent distribution of cells that support cell integrity for analysis and counting.  Proprietary stain and digital multispectral analysis produce results and images in just six minutes allowing technologists to focus on identification of abnormal or immature cells improving turnaround time compared traditional slide review.

Imagine a future where you are working side by side with your healthcare executives on large initiatives to reduce length of stay and readmission rates, push antibiotic stewardship and radically change the way healthcare is delivered. Roche Digital Diagnostics can help you achieve these goals by cultivating your lab data and other information sources to provide insights to help you streamline your ordering protocols and reduce financial waste. With the help of patient insights provided by Roche’s Digital Diagnostics portfolio, your institution will be ready to change how healthcare is delivered now and in the future.